114 related articles for article (PubMed ID: 37838303)
1. SERPINE1 and SERPINB7 as potential biomarkers for intravenous vitamin C treatment in non-small-cell lung cancer.
Ou J; Liao Q; Du Y; Xi W; Meng Q; Li K; Cai Q; Pang CLK
Free Radic Biol Med; 2023 Nov; 209(Pt 1):96-107. PubMed ID: 37838303
[TBL] [Abstract][Full Text] [Related]
2. Distinct prognostic values and potential drug targets of ALDH1 isoenzymes in non-small-cell lung cancer.
You Q; Guo H; Xu D
Drug Des Devel Ther; 2015; 9():5087-97. PubMed ID: 26366059
[TBL] [Abstract][Full Text] [Related]
3. MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin.
Zhao H; Xie YZ; Xing R; Sun M; Chi F; Zeng YC
Cell Oncol (Dordr); 2017 Aug; 40(4):357-365. PubMed ID: 28567715
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of an immune infiltrate-related competitive endogenous RNA network reveals potential prognostic biomarkers for non-small cell lung cancer.
Yang CZ; Hu LH; Huang ZY; Deng L; Guo W; Liu S; Xiao X; Yang HX; Lin JT; Sun LL; Lin LZ
PLoS One; 2021; 16(12):e0260720. PubMed ID: 34855841
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatic analysis revealing mitotic spindle assembly regulated NDC80 and MAD2L1 as prognostic biomarkers in non-small cell lung cancer development.
Wei R; Wang Z; Zhang Y; Wang B; Shen N; E L; Li X; Shang L; Shang Y; Yan W; Zhang X; Ma W; Wang C
BMC Med Genomics; 2020 Aug; 13(1):112. PubMed ID: 32795325
[TBL] [Abstract][Full Text] [Related]
6. Identification of Prognostic and Chemopredictive microRNAs for Non-Small-Cell Lung Cancer by Integrating SEER-Medicare Data.
Ye Q; Putila J; Raese R; Dong C; Qian Y; Dowlati A; Guo NL
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299277
[TBL] [Abstract][Full Text] [Related]
7. Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.
Galván-Femenía I; Guindo M; Duran X; Calabuig-Fariñas S; Mercader JM; Ramirez JL; Rosell R; Torrents D; Carreras A; Kohno T; Jantus-Lewintre E; Camps C; Perucho M; Sumoy L; Yokota J; de Cid R
Cancer Treat Res Commun; 2018; 15():21-31. PubMed ID: 30207284
[TBL] [Abstract][Full Text] [Related]
8. Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
Su Y; Long X; Song Y; Chen P; Li S; Yang H; Wu P; Wang Y; Bing Z; Cao Z; Cao L; Wu Y; Zhang Z; Liu J; Li B; Xiang J; Ma K; Zhang T; Zhang L; Mao X; Liu H; Xing P; Liang N
Target Oncol; 2019 Apr; 14(2):159-168. PubMed ID: 30895431
[TBL] [Abstract][Full Text] [Related]
9. A Comprehensive Bioinformatic Analysis for Identification of Myeloid-Associated Differentiation Marker as a Potential Negative Prognostic Biomarker in Non-Small-Cell Lung Cancer.
Zhou M; Chen Y; Gu X; Wang C
Pathol Oncol Res; 2022; 28():1610504. PubMed ID: 36061144
[No Abstract] [Full Text] [Related]
10. Bioinformatics analysis and experimental validation of TTK as a biomarker for prognosis in non-small cell lung cancer.
Chen J; Wu R; Xuan Y; Jiang M; Zeng Y
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32969465
[TBL] [Abstract][Full Text] [Related]
11. Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients.
Pavón MA; Arroyo-Solera I; Téllez-Gabriel M; León X; Virós D; López M; Gallardo A; Céspedes MV; Casanova I; López-Pousa A; Mangues MA; Quer M; Barnadas A; Mangues R
Oncotarget; 2015 Oct; 6(30):29016-33. PubMed ID: 26359694
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice.
Chung CT; Yeh KC; Lee CH; Chen YY; Ho PJ; Chang KY; Chen CH; Lai YK; Chen CT
Pharmacol Res; 2020 Nov; 161():105183. PubMed ID: 32896579
[TBL] [Abstract][Full Text] [Related]
13. UbcH10 expression provides a useful tool for the prognosis and treatment of non-small cell lung cancer.
Zhao L; Jiang L; Wang L; He J; Yu H; Sun G; Chen J; Xiu Q; Li B
J Cancer Res Clin Oncol; 2012 Nov; 138(11):1951-61. PubMed ID: 22760214
[TBL] [Abstract][Full Text] [Related]
14. Establishment of non-small-cell lung cancer risk prediction model based on prognosis-associated ADME genes.
Han K; Wang J; Qian K; Zhao T; Zhang Y
Biosci Rep; 2021 Oct; 41(10):. PubMed ID: 34522968
[TBL] [Abstract][Full Text] [Related]
15. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
[TBL] [Abstract][Full Text] [Related]
16. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
17. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
18. The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC.
Wang YD; Ha MW; Cheng J; Zhang WL; Cong X; Tong CY; Sun J
Oncol Rep; 2012 Apr; 27(4):979-86. PubMed ID: 22179630
[TBL] [Abstract][Full Text] [Related]
19. Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment.
Song L; Wang X; Cheng W; Wu Y; Liu M; Liu R; Zhang S; Xia H; Liu H; Tai X; Zhao H; Li X; Ji F
BMC Pulm Med; 2021 Dec; 21(1):420. PubMed ID: 34923982
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-383 is a tumor suppressor and potential prognostic biomarker in human non-small cell lung caner.
Shang Y; Zang A; Li J; Jia Y; Li X; Zhang L; Huo R; Yang J; Feng J; Ge K; Yang Y; Zhang Y; Jiang J
Biomed Pharmacother; 2016 Oct; 83():1175-1181. PubMed ID: 27551765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
